Emergent BioSolutions
EBS
$6.78
Share price
-5.44%
Change (1 day)
-54.10%
Change (1 year)
Categories
Emergent BioSolutions (EBS) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : $0.87 Billion USD
According to Emergent BioSolutions 's latest financial reports the company's total liabilities are $0.87 Billion USD. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Emergent BioSolutions - Total liabilities on balance sheet (from 2004 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | $0.90 B | -22.74% |
| 2023-12-31 | $1.17 B | -34% |
| 2022-12-31 | $1.77 B | 32.12% |
| 2021-12-31 | $1.34 B | -6.27% |
| 2020-12-31 | $1.43 B | 15.93% |
| 2019-12-31 | $1.23 B | 1.67% |
| 2018-12-31 | $1.21 B | 671.69% |
| 2017-12-31 | $0.15 B | -57.77% |
| 2016-12-31 | $0.37 B | -0.94% |
| 2015-12-31 | $0.37 B | -2.08% |
| 2014-12-31 | $0.38 B | 180.43% |
| 2013-12-31 | $0.13 B | 12.58% |
| 2012-12-31 | $0.12 B | -6.17% |
| 2011-12-31 | $0.13 B | 2.67% |
| 2010-12-31 | $0.12 B | 25.66% |
| 2009-12-31 | $0.10 B | 10.32% |
| 2008-12-31 | $91.43 M | -10.66% |
| 2007-12-31 | $0.10 B | 2.57% |
| 2006-12-31 | $99.78 M | 145.8% |
| 2005-12-31 | $40.59 M | -11.95% |
| 2004-12-31 | $46.1 M | |
| 2002-12-31 | $18.63 M | -67.71% |
| 2001-12-31 | $57.71 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Merck MRK | $66.72 B | 7,539.34% | 🇺🇸 USA |
 SIGA Technologies SIGA | $30.93 M | -96.46% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $60.79 B | 6,860.63% | 🇬🇧 UK |
 Celldex Therapeutics CLDX | $36.49 M | -95.82% | 🇺🇸 USA |
 Pfizer PFE | $117.39 B | 13,340.69% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $32.14 B | 3,580.56% | 🇮🇱 Israel |
 Soligenix SNGX | $4.13 M | -99.53% | 🇺🇸 USA |